Penn Pharmaceutical Services has reported strong sales figures for
the fifth consecutive year, with a key driver of recent growth
being attributed to a boom in contract manufacturing as well as
small-scale commercial batches.
Cambrex has recorded a gain in the third quarter of this year, with
growth in its Bioproducts and Human Health segments. The company's
troublesome BioPharma division continues to underperform,
indicative of a market for outsourced...
Cardinal Health reported a varied first quarter, with sales and
income receiving substantial gains due to across-the-board
improvement in pharmaceutical distribution, medical products and
services and clinical technologies.
Arsenal Capital Partners has acquired a majority stake in Reilly
Industries for €209 million and Velsicol Chemical for an
undisclosed fee. The purchases continue a rich vein of activity for
the private equity firm, which now hold...
Drug packaging maker West Pharmaceutical Services release its 3Q
results, which indicate a rise in profits but fell short of analyst
estimates, due to slow sales in some segments and high raw material
and energy costs.
Bruker AXS, a subsidiary of the Bruker BioSciences Corporation, has
announced an agreement to purchase Roentec, an x-ray microanalysis
instrumentation company that signals Bruker's intention to
reinforce its standing within this...
Dutch pharmaceuticals and chemicals giant Akzo Nobel reported
third-quarter sales of €3,29 billion, a slight decrease from the
previous quarter but up 5.4 per cent from the comparable period in
2004, thanks to growth in all its units,...
The GEA Group has acquired the manufacturer of freeze dryers for
pharmaceutical products, STERIS, a unit of US-based STERIS
Corporation in a deal that aims to strengthen the group's Process
Engineering Division in the Process...
BASF has announced it is to reduce production at one of its main
sites in a move that reflects the declining demand for
pseudoephedrine and caffeine caused by a change in prescription
regulations and pricing pressures.
Pharmaceutical manufacturers, Wyeth, are to phase out manufacturing
at its US facility as part of its consolidation plans, which will
see the gradual phasing out of all operations at the New York
facility by late 2008.